ABSTRACT
Preimplantation genetic testing (PGT) has been introduced in in vitro fertilization (IVF) to identify the embryos affected from single gene diseases (PGT-M), structural chromosomal aberration (PGT-SR), or chromosomal aneuploidies (PGT-A). However, invasive oocyte/embryo biopsy approaches are required to conduct PGT. Some studies evaluated the impact of biopsy on the sustained implantation/live birth rates, but little evidence has been produced to assess obstetric, perinatal, and long term postnatal outcomes after PGT. In this chapter, we summarized the data published to address this issue. To date, the reports highlighted in PGT-derived newborns with respect to conventional IVF-derived ones (1) a higher prevalence of placenta previa in case of polar body biopsy, (2) a longer admission in neonatal intensive care units and a higher prevalence of cesarean section in case of blastomere biopsy, and (3) a higher prevalence of preeclampsia in case of trophectoderm biopsy. Far more data are required to adjust for the risk of bias in these reports, yet the evidence so far is reassuring towards the short and long term safety of these techniques.
